Reduction of pain due to propofol by ondansetron or lignocaine - a comparative study

Comparison of ondansetron or lignocaine pretreatment for reduction in pain due to propofol intravenous injection: Single blind randomized study

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/05/013827

Enrollment

546

Registered

2018-05-11

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Pain due to propofol administration

Interventions

Intervention1: Ondansetron: Injection ondansetron 4mg(2ml) intravenously for a period of 10 seconds Control Intervention1: Lignocaine: Injection 2ml(20mg) of 1% lignocaine intravenously for a period

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients of either gender aged between 21- 50 years 2.Patients with body weight of 50-80 Kg 3.Patients undergoing elective surgeryunder general anesthesia 4.Patients belonging to American Society of Anesthesiology (ASA) physical status I and II

Exclusion criteria

Exclusion criteria: 1.History of allergy to study drugs 2.Pregnant and lactating women 3.Patients receiving analgesics 48 hours before surgery 4.Patients with pain posted for elective surgery

Design outcomes

Primary

Measure	Time frame
To compare the effect of ondansetron and lignocaine in reducing pain following propofol injection using Verbal Rating Scale (VRS)Timepoint: Baseline and 15 seconds after propofol injection intravenoulsy	—

Secondary

Measure	Time frame
To assess the adverse effect in both groups using WHO causality assessment and Naranjo probability scalesTimepoint: Study drugs administration to 6 hrs postoperatively	—

Countries

India

Contacts

Public ContactBhuvana K

Sri Devaraj Urs Medical College

drbhuvanak2010@gmail.com9900383738

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026